摘要
评估尿核基质蛋白 2 2 (NMP2 2 )作为尿路上皮癌肿瘤标记物的临床诊断价值。应用免疫酶标记法 (ELISA)检测 2 4例尿路上皮癌 ,2 0例非尿路上皮癌 ,6例膀胱全切术后肠道膀胱患者尿NMP2 2水平。结果发现 ,尿路上皮癌组的尿NMP2 2平均为 39 4 9U/ml,明显高于非尿路上皮癌组的 4 .33U/ml(P <0 0 1) ,尿路上皮癌治疗后患者尿NMP2 2水平下降至 5 0 8U/ml(P <0 0 1) ,膀胱癌全切术后肠道膀胱患者尿NMP2 2水平极高。提示尿NMP2 2作为尿路上皮癌的肿瘤标记物具有较高特异性 。
To evaluate the clinical value of NMP22 for the diagnosis of urothelial cancer. Urinary NMP22 was determined with enzyme linked immunoaorbent assay (ELISA) in 50 patients in whom 24 patients were suffering from cancer of urothelium, and 20 cases of cancer of other origins, and 6 cases of artificial bladder after total cystectomy for cancer. The median NMP22 value of urothelial cancer was 37 49U/ml, which was significantly higher than those of other patients (4 33U/ml, P <0 01). The level of NMP22 was lowered after removal of urothelial cancer, resulting in a mean value of 5.08U/ml( P <0 01). The NMP22 value of patients after radical cystectomy for cancer and intestinal neobladder was very high. Urinary NMP22 is a very specific tumor marker for the diagnosis of urothelial cancers.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2003年第4期369-370,共2页
Medical Journal of Chinese People's Liberation Army
关键词
尿
NMP22
诊断
尿路上皮癌
应用
urinary
unclear matrix protein22(NMP22)
urothelial cancer
